NEJM:两款新药可治疗致命性肺癌
2014/05/22
药物Nintedanib和Pirfenidone是治疗致命性肺癌——特发性肺纤维化肺癌的两种实验室药物,尽管它们会引起湿疹、反胃等不良副作用,但是它们可能是医治并延长这些病人寿命的唯一两种药物。


最近,研究者首次找到了治疗致命性肺癌——特发性肺纤维化(diopathic pulmonary fibrosis)的药物。

虽然,研究者发现这两种药物可能达不到治愈病人的目标,但是该药物能缓解病人病情的进一步恶化。相关研究发表在最新一期的《新英格兰杂志》上。

该病每年在美国发生率大约有8万例,通常患者呼吸困难,3-4年后死亡。医生也对患有这种病症的病人毫无应对策略,唯一能够做的就是缓解病人的咳嗽。

尽管这种药物不能治愈病人,但是很多病人仍会非常高兴看到它出现,它既能稳定病人的病情,且能够延长病人的寿命。人们都对这两款新药寄予厚望,但是这项研究的作者波士顿布里格女子医院(Brigham and Women’s Hospital)Gary M. Hunninghake博士称,“目前对它发挥作用的机理,我们目前尚未知晓。”

该药物目前还是实验性用药,FDA并未批准该药物。事实上,一旦患上这个肺病之后,病人想知道的是自己还能够活多久,他们并不在乎该药物是否被FDA批准。

这两种药物还有副作用,nintedanib会引起痢疾,pirfenidone会引起湿疹和反胃。同这种病引起的严重后果来看,患者似乎并不太在乎这些副作用。

此外,这种疾病在吸烟者身上较为更多发现,但是对于一些非吸烟者,他们同样也有很高的患病比例。
所有文章仅代表作者观点,不代表本站立场。如若转载请联系原作者。
查看更多
  • A New Hope for Idiopathic Pulmonary Fibrosis

    I suspect that many of my patients have picked up on more than a hint of frustration in my voice when I tell them that the cause of their shortness of breath is idiopathic pulmonary fibrosis. This frustration stems from the fact that beyond providing information about prognosis or referral for lung transplantation or palliation, there has been little to offer in the way of treatment. Idiopathic pulmonary fibrosis is a chronic, progressive disorder of lung scarring that predominantly affects older patients and has a death rate worse than that of many cancers (3-year survival, 50%).1 However, in contrast to most cancers, there has been limited, and sometimes conflicting,2 evidence that any drug could alter the course of this disease. The game has now changed. With the publication of the INPULSIS-1 and INPULSIS-2 trials3 and the ASCEND (Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis) trial4 in the Journal, we may soon have choices in the medical management of idiopathic pulmonary fibrosis.

    展开 收起
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test